longevity
Evaluates longevity interventions using evidence tiers. Provides research evaluation framework and curated high-value insights on supplements, sleep, exercise, and protocols. Activate for anti-aging, healthspan, supplement evaluation, or research paper analysis.
安装 / 下载方式
TotalClaw CLI推荐
totalclaw install clawskills:clawskills~lofimichael-longevity-assistantcURL直接下载,无需登录
curl -fsSL https://skills.taituai.com/api/skills/clawskills%3Aclawskills~lofimichael-longevity-assistant/file -o lofimichael-longevity-assistant.md# Longevity Research Framework Evidence-based longevity evaluation assistant. Teaches how to assess interventions using research methodology, not prescription. Provides curated non-obvious insights demonstrating the evaluation framework. ## When to Activate Trigger keywords: longevity, anti-aging, healthspan, lifespan, supplement evaluation, research paper analysis, evidence tier, biomarker interpretation, sleep optimization, exercise protocol, Bryan Johnson, Blueprint, mitochondria, autophagy, senolytics. ## Evidence Tiers | Tier | Definition | Example | |------|------------|---------| | **A** | Multiple RCTs, meta-analyses, consistent results | Creatine for muscle | | **B** | Single RCT or large cohort, emerging human data | Urolithin-A | | **C** | Mechanistic/animal studies, small human trials | Most senolytics | | **D** | Anecdotal, theoretical, n=1 | Novel peptides | ## Research Evaluation Framework ### Study Design Hierarchy 1. Systematic review / meta-analysis 2. Randomized controlled trial (RCT) 3. Cohort study (prospective > retrospective) 4. Case-control study 5. Case series / case reports 6. Mechanistic / animal studies 7. Expert opinion / theoretical ### Assessment Checklist - **Sample size**: Adequately powered? (n>100 for most outcomes) - **Duration**: Appropriate for endpoint? (bone density needs years, not weeks) - **Population**: Relevant to you? (young athletes ≠ older adults) - **Effect size**: Clinically meaningful or just statistically significant? - **Replication**: Confirmed by independent groups? - **Conflict of interest**: Industry-funded? Disclosed relationships? ### Red Flags - Single study with extraordinary claims - Surrogate endpoints only (biomarker change without clinical outcome) - Cherry-picked timepoints or subgroups - No control group or inadequate blinding - Massive effect sizes (>50% improvement = suspicious) - Published only in predatory journals - Funded entirely by supplement manufacturer - Authors selling the product --- ## Alpha Discovery Framework Use these patterns to identify non-obvious insights in longevity research: ### Dosing Assumptions - Standard dose may not apply to all outcomes (tissue-specific thresholds) - "More is better" often has inverse U-curve (melatonin, antioxidants) - Saturation points differ by target (muscle vs. brain for creatine) ### Timing & Context - Relative timing matters (cold exposure vs. training window) - Circadian timing affects efficacy (eating window, supplement timing) - Cycling may be required (adaptation, tolerance, microbiome shifts) ### Form & Bioavailability - Same compound, different absorption (ethyl ester vs. triglyceride omega-3) - Conversion dependencies (ellagitannins → urolithin-A requires specific gut bacteria) - Cofactor requirements (fat-soluble vitamins need dietary fat) ### Synergies & Antagonisms - Required pairings (D3 without K2 may cause harm) - Absorption competition (calcium and magnesium compete) - Timing conflicts (iron and coffee, cold and hypertrophy) ### Population Specificity - Age-dependent responses (fasting + muscle loss in older adults) - Sex differences in metabolism - Genetic responders vs. non-responders (APOE and saturated fat) ### Mechanism vs. Outcome - Plausible mechanism ≠ proven clinical benefit - Surrogate endpoints (biomarkers) ≠ real outcomes (mortality, function) - Animal doses rarely translate directly to humans --- ## Example Alpha The following examples demonstrate the discovery framework above. These are illustrative, not exhaustive—use the framework to evaluate new interventions. ### Creatine: 15g for Cognitive Benefits - **Common belief**: 5g saturates muscle, same dose works for brain - **Alpha**: Serum creatine must rise high enough to cross blood-brain barrier and increase brain phosphocreatine. 5g saturates muscle but doesn't reliably raise brain levels. - **Evidence**: Multiple studies show cognitive benefits at 15-20g; 5g studies often null for cognition - **Tier**: B (emerging human data, mechanism understood) - **Practical**: Split 15g into 3x5g doses to avoid GI distress ### Melatonin: 300mcg Outperforms 1mg+ - **Common belief**: More melatonin = better sleep - **Alpha**: Body produces ~300mcg endogenously. Supraphysiological doses (1-10mg) cause next-day grogginess, may affect cognition long-term, and create dependency via receptor downregulation. - **Evidence**: Meta-analyses show 300mcg effective; higher doses don't improve outcomes - **Tier**: A (multiple meta-analyses) - **Practical**: Start at 300mcg; most commercial products are 10-30x too high ### Urolithin-A: Mitophagy Without Pomegranate Roulette - **Common belief**: Eat pomegranates for mitochondrial health - **Alpha**: Urolithin-A (the active compound) requires gut bacteria conversion from ellagitannins. Only ~40% of people have the right microbiome. Direct supplementation bypasses this. - **Evidence**: PMC9133463, Timeline nutrition RCTs show mitophagy activation - **Tier**: B (human RCTs, mechanism validated) - **Practical**: 500-1000mg daily; one of few compounds with direct mitophagy evidence in humans ### Sleep Timing > Sleep Duration - **Common belief**: Get 8 hours, timing doesn't matter - **Alpha**: Circadian rhythm governs 100+ physiological processes. Shifting sleep window by 2 hours causes more dysfunction than losing 1-2 hours of sleep. Late sleep (2am-10am) worse than short sleep (11pm-6am). - **Evidence**: Chronobiology research, shift-worker health outcomes - **Tier**: A (strong epidemiological + mechanistic) - **Practical**: Consistent bed/wake times matter more than duration optimization ### Skin Damage: Cumulative and Irreversible - **Common belief**: Damage can be repaired with skincare products - **Alpha**: UV exposure causes cumulative DNA damage. Photoaging is largely irreversible. Prevention (sunscreen, clothing) has 100x ROI vs. treatment. - **Evidence**: Dermatology consensus, twin studies - **Tier**: A (decades of evidence) - **Practical**: Daily SPF 30+ on face/hands is highest-yield longevity intervention for appearance ### Zone 2 Cardio: Mitochondrial Biogenesis - **Common belief**: HIIT is more efficient, Zone 2 is wasted time - **Alpha**: Zone 2 (can talk but not sing) specifically drives mitochondrial biogenesis and fat oxidation capacity. HIIT builds different adaptations. Both needed, but Zone 2 is undervalued. - **Evidence**: Exercise physiology, Inigo San Millan research - **Tier**: A (extensive mechanistic + performance data) - **Practical**: 3-4 hours/week Zone 2; most people go too hard and miss the adaptation ### Cold Exposure: Timing Matters for Hypertrophy - **Common belief**: Cold exposure is universally beneficial - **Alpha**: Cold within 4 hours post-strength training blunts muscle protein synthesis and hypertrophy signaling. The inflammatory response you're suppressing is required for adaptation. - **Evidence**: Multiple mechanism studies, athletic performance research - **Tier**: B (consistent mechanism data, some human trials) - **Practical**: Cold exposure on rest days or 6+ hours after strength training ### Berberine: Cycling Required - **Common belief**: Take daily like other supplements - **Alpha**: GI microbiome adapts to berberine, reducing effectiveness. Also, berberine's metformin-like effects may blunt some exercise adaptations. - **Evidence**: Clinical practice patterns, mechanism studies - **Tier**: B (clinical consensus, mechanism understood) - **Practical**: 4-6 weeks on, 2 weeks off; avoid on heavy training days ### K2 (MK-7) + D3: Required Pairing - **Common belief**: Vitamin D alone is fine - **Alpha**: D3 increases calcium absorption. Without K2 to direct calcium to bones, it may deposit in arteries. K2 activates matrix-GLA protein and osteocalcin. - **Evidence**: Multiple RCTs, Rotterdam Study correlations - **Tier**: B (mechanistically clear, human outcome data emerging) - **Practical**: 100-200mcg MK-7 per 5000 IU D3; take together with fa